213
Participants
Start Date
October 31, 2006
Primary Completion Date
July 31, 2010
Study Completion Date
September 30, 2010
mesalazine (Asacol®)
800 mg tablets
Barnsley District General Hospital, Barnsley
North Hampshire Hospital, Basingstoke
Birmingham Heartlands Hospital, Birmingham
Selly Oak Hospital, Birmingham
Bishop Auckland General Hospital, Bishop Auckland
Blackpool Victoria Hospital, Blackpool
Glan Clwyd Hospital, Bodelwyddan
Pilgrim Hospital, Boston
Princess Royal Hospital, Brighton
Royal Sussex County Hospital, Brighton
Bristol Royal Infirmary, Bristol
Llandough Hospital, Cardiff
University Hospital of Wales, Cardiff
Cumberland Infirmary, Carlisle
Walsgrave Hospital, Coventry
Derby City General Hospital, Derby
Dr M Al-Najjar, Doncaster
Russells Hall Hospital, Dudley
University Hospital of North Durham, Durham
Stobhill Hospital, Glasgow
Gloucester Royal Hospital, Gloucester
University Hospital of Hartlepool, Hartlepool
Hull Royal Infirmary, Hull
Royal Glamorgan Hospital, Llantrisant
County Hospital, Louth
Luton & Dunstable Hospital, Luton
Macclesfield District General Hospital, Macclesfield
Borders General Hospital, Melrose
Prince Charles Hospital, Merthyr Tydfil
Norfolk and Norwich University Hospitals NHS Foundation Trust, Norwich
Derriford Hospital, Plymouth
Poole General Hospital, Poole
Queen Alexandra Hospital, Portsmouth
Royal Berkshire Hospital, Reading
Rotherham District General Hospital, Rotherham
Royal Hallamshire Hospital, Sheffield
University Hospital of North Tees & University Hospital of Hartlepool, Stockton-on-Tees
Royal Cornwall Hospital, Truro
Queen Elizabeth II Hospital, Welwyn Garden City
New Cross Hospital, Wolverhampton
Alexandra Hospital, Worcester
Worcester Royal Infirmary, Worcester
Worthing Hospital, Worthing
Yeovil District Hospital, Yeovil
York District Hospital, York
Procter and Gamble
INDUSTRY
Cardiff and Vale University Health Board
OTHER_GOV